Target: PD-1

PD-1 (the programmed cell death protein 1, CD279) is a cell surface receptor that, along with its ligand (PD-L1), plays a role in our immune system’s response to our own cells. Unfortunately, this mechanism can prevent our immune system from killing cancer cell. Thus, it’s a common therapeutic target in many cancers.

Today, there are a few anti-PD-1 monoclonal antibodies that are used as combination therapies in cancers including melanoma, Hodgkin’s lymphoma, renal cell carcinoma, and certain lung cancers. As always, there’s still room for improvement.

So, we’ve made our own using AI.